Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07195552 · ClinicalTrials.gov registry record · NA
Clinical Trial: Rapid Immune Modulating Effects
A NA study of Immune Surveillance, sponsored by Natural Immune Systems.
- Recruiting
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07195552: Recruiting NA study of Immune Surveillance, sponsored by Natural Immune Systems.
NCT07195552 is a NA study of Immune Surveillance that is actively recruiting participants, run by Natural Immune Systems. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07195552, a NA study of Immune Surveillance, is actively recruiting participants, sponsored by Natural Immune Systems.
- RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal for this clinical trial is to compare the immune effects of three different medicinal mushrooms to a placebo. The mushrooms include Agaricus, Reishi, and Turkey Tail.
Primary Outcome
Changes to serum cytokine levels. The testing involves a broad panel of pro- and anti-inflammatory cytokines, anti-viral peptides, and regenerative growth factors, using a 27-plex Luminex magnetic bead array and the MagPix® multiplexing system. The following cytokines are tested: IL-1beta, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, eotaxin, basic FGF, G-CSF, GM-CSF, IFN-gamma, IP-10, MCP-1 (MCAF), MIP-1alpha, MIP-1beta, PDGF-BB, RANTES, TNF-alpha,
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Agaricus blazei
- DIETARY_SUPPLEMENT Reishi
- DIETARY_SUPPLEMENT Turkey Tail
Study Locations (1)
Oregon
- NIS Labs - Klamath Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-12 |
| Phase | NA |
What NCT07195552 shows while recruiting
NCT07195552 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Immune Surveillance appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07195552 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT07195552 about?
NCT07195552 is a clinical study titled "Clinical Trial: Rapid Immune Modulating Effects". The goal for this clinical trial is to compare the immune effects of three different medicinal mushrooms to a placebo. The mushrooms include Agaricus, Reishi, and Turkey Tail.
What is the current status of trial NCT07195552?
This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2024-07-01. Estimated completion is 2025-12.
What conditions does trial NCT07195552 study?
This clinical trial studies the following conditions: Immune Surveillance.
What interventions are being tested in trial NCT07195552?
The interventions under investigation include: Placebo (OTHER), Agaricus blazei (DIETARY_SUPPLEMENT), Reishi (DIETARY_SUPPLEMENT), Turkey Tail (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07195552?
This trial is sponsored by Natural Immune Systems, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07195552 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Surveillance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07195552's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI